1. Generics Bulletin

Teva Seeks Global Resolution Of Opioid Litigation

Bellwether Trial In US Is Halted By Settlement Agreement

 
• By Brenda Sandburg

Teva and three distributors settle with two plaintiffs; PBMs are defendants in next case as Teva also reaches an agreement in principal with four attorneys general for global settlement framework.

PS1910_Opiod-gavel_1490385098_1200.jpg
Teva seeks to settles opioid litigation • Source: Shutterstock

Teva Pharmaceutical Industries Ltd. and the three largest drug distributors put a halt to the first opioid bellwether trial by reaching an agreement in principle with the two plaintiffs just before opening statements were to begin. The move gives them more time to reach a global settlement to resolve the more than 2,000 other suits pending against them and other companies.

The three distributors – AmerisourceBergen Corp., Cardinal Health Inc. and McKesson Corp

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Generics Bulletin

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.